These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 27485569)

  • 21. The discovery of aryl-2-nitroethyl triamino pyrimidines as anti-Trypanosoma brucei agents.
    Linciano P; Pozzi C; Tassone G; Landi G; Mangani S; Santucci M; Luciani R; Ferrari S; Santarem N; Tagliazucchi L; Cordeiro-da-Silva A; Tonelli M; Tondi D; Bertarini L; Gul S; Witt G; Moraes CB; Costantino L; Costi MP
    Eur J Med Chem; 2024 Jan; 264():115946. PubMed ID: 38043491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Silico Identification and In Vitro Evaluation of Natural Inhibitors of Leishmania major Pteridine Reductase I.
    Herrmann FC; Sivakumar N; Jose J; Costi MP; Pozzi C; Schmidt TJ
    Molecules; 2017 Dec; 22(12):. PubMed ID: 29211037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repurposing the Trypanosomatidic GSK Kinetobox for the Inhibition of Parasitic Pteridine and Dihydrofolate Reductases.
    Santucci M; Luciani R; Gianquinto E; Pozzi C; Pisa FD; Dello Iacono L; Landi G; Tagliazucchi L; Mangani S; Spyrakis F; Costi MP
    Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multitarget, Selective Compound Design Yields Potent Inhibitors of a Kinetoplastid Pteridine Reductase 1.
    Pöhner I; Quotadamo A; Panecka-Hofman J; Luciani R; Santucci M; Linciano P; Landi G; Di Pisa F; Dello Iacono L; Pozzi C; Mangani S; Gul S; Witt G; Ellinger B; Kuzikov M; Santarem N; Cordeiro-da-Silva A; Costi MP; Venturelli A; Wade RC
    J Med Chem; 2022 Jul; 65(13):9011-9033. PubMed ID: 35675511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of potential HIV-1 integrase strand transfer inhibitors: in silico virtual screening and QM/MM docking studies.
    Reddy KK; Singh SK; Tripathi SK; Selvaraj C
    SAR QSAR Environ Res; 2013; 24(7):581-95. PubMed ID: 23521430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dissecting the metabolic roles of pteridine reductase 1 in Trypanosoma brucei and Leishmania major.
    Ong HB; Sienkiewicz N; Wyllie S; Fairlamb AH
    J Biol Chem; 2011 Mar; 286(12):10429-38. PubMed ID: 21239486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
    Halder AK; Saha A; Saha KD; Jha T
    J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer's agents.
    Ambure P; Kar S; Roy K
    Biosystems; 2014 Feb; 116():10-20. PubMed ID: 24325852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
    Vyas VK; Ghate M; Goel A
    J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
    Islam MA; Pillay TS
    J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
    Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
    Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An integrated approach towards the discovery of novel non-nucleoside Leishmania major pteridine reductase 1 inhibitors.
    Leite FHA; Froes TQ; da Silva SG; de Souza EIM; Vital-Fujii DG; Trossini GHG; Pita SSDR; Castilho MS
    Eur J Med Chem; 2017 May; 132():322-332. PubMed ID: 28407565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and biological evaluation of novel inhibitors of Trypanosoma brucei pteridine reductase 1.
    Spinks D; Ong HB; Mpamhanga CP; Shanks EJ; Robinson DA; Collie IT; Read KD; Frearson JA; Wyatt PG; Brenk R; Fairlamb AH; Gilbert IH
    ChemMedChem; 2011 Feb; 6(2):302-8. PubMed ID: 21275054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thiadiazine-thiones as inhibitors of leishmania pteridine reductase (PTR1) target: investigations and in silico approach.
    Shtaiwi A
    J Biomol Struct Dyn; 2023 Aug; ():1-10. PubMed ID: 37578348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One scaffold, three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening.
    Mpamhanga CP; Spinks D; Tulloch LB; Shanks EJ; Robinson DA; Collie IT; Fairlamb AH; Wyatt PG; Frearson JA; Hunter WN; Gilbert IH; Brenk R
    J Med Chem; 2009 Jul; 52(14):4454-65. PubMed ID: 19527033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and biological evaluation of potent azadipeptide nitrile inhibitors and activity-based probes as promising anti-Trypanosoma brucei agents.
    Yang PY; Wang M; Li L; Wu H; He CY; Yao SQ
    Chemistry; 2012 May; 18(21):6528-41. PubMed ID: 22488888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploration of new scaffolds as potential MAO-A inhibitors using pharmacophore and 3D-QSAR based in silico screening.
    Shelke SM; Bhosale SH; Dash RC; Suryawanshi MR; Mahadik KR
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2419-24. PubMed ID: 21397504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacophore identification of ascofuranone, potent inhibitor of cyanide-insensitive alternative oxidase of Trypanosoma brucei.
    Saimoto H; Kido Y; Haga Y; Sakamoto K; Kita K
    J Biochem; 2013 Mar; 153(3):267-73. PubMed ID: 23180806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacophore Identification, Molecular Docking, Virtual Screening, and In Silico ADME Studies of Non-Nucleoside Reverse Transcriptase Inhibitors.
    Pirhadi S; Ghasemi JB
    Mol Inform; 2012 Dec; 31(11-12):856-66. PubMed ID: 27476739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemometric design to explore pharmacophore features of BACE inhibitors for controlling Alzheimer's disease.
    Hossain T; Mukherjee A; Saha A
    Mol Biosyst; 2015 Feb; 11(2):549-57. PubMed ID: 25435329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.